Credit Suisse analyst A.J. Rice tells investors in a research note that the award of the TRICARE East and West contracts is a win for Humana (HUM), but a loss for Centene (CNC). For Humana, the company has already contemplated a shift in lives from the contract, but Rice believes Centene did not contemplate the loss of the TRICARE contract in their 2024 planning. While the loss of the business is disappointing for Centene, the impact is relatively modest compared to other contracts such as the CA Medicaid contract, Rice contends.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on HUM:
- Humana wins Defense Department TRICARE East Region Contract
- ‘Load Up,’ Says Jim Cramer About These 2 ‘Strong Buy’ Healthcare Stocks
- Humana put volume heavy and directionally bearish
- Humana upgraded to Buy at Goldman Sachs on improved competitive position
- Humana upgraded to Buy from Neutral at Goldman Sachs